Pure Global
NCT06328049

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC

A Prospective, Single-arm, Exploratory Clinical Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer
Taixing People's Hospital·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
NSCLC
Drug/Device/Intervention
Trilaciclib Injection
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Taixing People's Hospital
Location
Taixing, China
Timeline & enrollment
Phase
Phase 2
Start date
Aug 10, 2023
End date
Aug 10, 2025
Enrollment
30 participants
Primary outcome

Incidence of febrile neutropenia (FN)

Summary

The aim of this study is to investigate the safety and efficacy of the prophylactic use of
 Trilaciclib in patients with non-small cell lung cancer (NSCLC) receiving platinum-based
 chemotherapy, so as to provide more evidence-based medical evidence for the optimal diagnosis
 and treatment strategy in this population.

Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06328049
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06328049 through Pure Global AI's free database. This Phase 2 trial is sponsored by Taixing People's Hospital and is currently Recruiting. The study focuses on NSCLC. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.